Equities analysts expect that AngioDynamics, Inc. (NASDAQ:ANGO) will post $88.90 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for AngioDynamics’ earnings. The lowest sales estimate is $87.70 million and the highest is $90.10 million. AngioDynamics reported sales of $86.71 million in the same quarter last year, which indicates a positive year over year growth rate of 2.5%. The company is scheduled to report its next quarterly earnings report on Thursday, January 3rd.
On average, analysts expect that AngioDynamics will report full-year sales of $357.05 million for the current year, with estimates ranging from $355.70 million to $358.39 million. For the next year, analysts forecast that the firm will post sales of $366.72 million, with estimates ranging from $364.50 million to $368.94 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow AngioDynamics.
AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Thursday, September 27th. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). AngioDynamics had a net margin of 4.62% and a return on equity of 5.44%. The firm had revenue of $85.34 million during the quarter, compared to analyst estimates of $84.05 million. During the same quarter in the previous year, the business posted $0.13 earnings per share. The business’s quarterly revenue was down .1% compared to the same quarter last year.
A number of research analysts recently issued reports on the stock. BidaskClub upgraded shares of AngioDynamics from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 28th. Zacks Investment Research upgraded shares of AngioDynamics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 11th. Canaccord Genuity reiterated a “hold” rating and issued a $20.00 target price on shares of AngioDynamics in a research note on Thursday, July 12th. Finally, Raymond James lowered shares of AngioDynamics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 11th. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. AngioDynamics presently has a consensus rating of “Buy” and a consensus price target of $18.44.
NASDAQ:ANGO traded up $0.23 during midday trading on Thursday, reaching $20.17. The stock had a trading volume of 141,179 shares, compared to its average volume of 244,348. AngioDynamics has a 1-year low of $15.16 and a 1-year high of $24.49. The company has a current ratio of 2.64, a quick ratio of 1.55 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $747.63 million, a PE ratio of 27.26 and a beta of 0.86.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its position in AngioDynamics by 7.3% in the 2nd quarter. BlackRock Inc. now owns 5,478,788 shares of the medical instruments supplier’s stock worth $121,848,000 after purchasing an additional 374,834 shares during the last quarter. Janus Henderson Group PLC grew its position in AngioDynamics by 0.3% in the 2nd quarter. Janus Henderson Group PLC now owns 1,802,894 shares of the medical instruments supplier’s stock worth $40,096,000 after purchasing an additional 6,027 shares during the last quarter. Northern Trust Corp grew its position in AngioDynamics by 0.8% in the 2nd quarter. Northern Trust Corp now owns 1,209,647 shares of the medical instruments supplier’s stock worth $26,903,000 after purchasing an additional 9,119 shares during the last quarter. Segall Bryant & Hamill LLC grew its position in AngioDynamics by 18.1% in the 2nd quarter. Segall Bryant & Hamill LLC now owns 769,732 shares of the medical instruments supplier’s stock worth $17,119,000 after purchasing an additional 117,950 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in AngioDynamics by 1.0% in the 2nd quarter. Renaissance Technologies LLC now owns 647,600 shares of the medical instruments supplier’s stock worth $14,403,000 after purchasing an additional 6,500 shares during the last quarter. Institutional investors own 97.44% of the company’s stock.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Read More: Float
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.